Amphion Portfolio Company WellGen Completes $3M Funding
News Feb 23, 2006
The capital raised from this latest round of financing will provide additional resources for WellGen to begin clinical studies in humans under its Obesity and Inflammation Programmes, aimed at developing and bringing to market a variety of new and promising nutritional products on which the company is working.
Investors in this round of financing include both new and existing WellGen shareholders. Amphion’s $1MM investment, previously announced in August 2005, brings its ownership stake in the firm to 19%.
WellGen’s Obesity Programme is based upon the study of a proprietary gene panel comprised of carefully selected genes that are known to be associated with obesity.
Functional food ingredients coming out of this programme are anticipated to control weight via a gene-controlling mechanism of action that is different from those of other products on the market.
Encouraged by animal studies that were completed in late 2005, WellGen anticipates beginning human clinical studies during 2006.
Richard Morgan, CEO of Amphion, said, "With obesity reaching almost epidemic proportions, there is a vast and growing need for safe and effective bioactives to address this important market."
"We are pleased to see WellGen’s patented screening technologies addressing obesity, inflammation, and other equally serious conditions and we’re excited to increase our investment."
David Evans, chief executive officer of WellGen, said, "We are pleased with the results that we are seeing and that our shareholders have confidence in WellGen’s ability to identify, develop and successfully commercialize consequential ingredients for the wellness market."
Single Gene Change in Gut Bacteria Alters Host MetabolismNews
Scientists have found that deleting a single gene in a particular strain of gut bacteria causes changes in metabolism and reduced weight gain in mice. The research provides an important step towards understanding how the microbiome – the bacteria that live in our body – affects metabolism.READ MORE
Gotta Sample 'Em All! Underwater Pokéball Captures Ocean LifeNews
A new device developed by Wyss Institute reseachers safely traps delicate sea creatures inside a folding polyhedral enclosure and lets them go without harm using a novel, origami-inspired design. The ultimate aim is to allow the sea creatures to be (gently) analyzed in high detail.READ MORE
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018